Just as a reminder, MDVN is an Aggressive stock. So, you should stick with my 60%, 30%, 10% rule with MDVN stock. Keeping that in mind, Medivation is a “strong buy.”
Medivation, Inc. (MDVN) was a big mover last session, as its shares rose nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend for the …
But the FDA was presumably able to review XTANDI's phase III data quite rapidly. XTANDI was approved on August 31st. The prolonged rally in MDVN stock can be traced back to a press release on November 3rd, 2011 that had statements …
Biogen closed Wednesday up over 1% at $305.69. Medivation Inc. (NASDAQ: MDVN) is a stock the Stifel analyst are very bullish on, and they are way above street estimates for earnings. They attribute the higher number to higher forecast …
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only ... At Medivation ( MDVN), a filing with the SEC revealed that on Friday, …
Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >> ONCOLYTICS BIOTECH INC (ONCY): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report ILLUMINA INC (ILMN): …
MDVN’s niche is research into other diseases for which few treatment options exist, but none of this new research is close enough to warrant owning the stock at $129 a share. Well, yipsee doodle dandy, I like your selection of Universal …
MDVN). Pfizer now expects to complete the acquisition in the Third-Quarter 2016. The closing of the tender offer remains subject to other customary closing conditions, including the tender of a majority of the outstanding shares of Medivation …
Deutsche Bank has a rating of Hold on the stock and a $26 price target. The consensus target is higher at $27.09. Shares closed trading at $25.13. Medivation Inc. (NASDAQ: MDVN) is a stock many Wall Street analysts are very bullish on. …
A California Superior Court judge has ruled against Medivation, Inc. (NASDAQ:MDVN) in the case of Medivation ... and is likely to become a blockbuster drug as many expect and the stock price indicates. However, ARN-509's potential …